Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Key Takeaways Retatrutide is an investigational weight-loss drug showing strong results in trials, but it is not FDA-approved yet
:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)
Exceeding recommended serving may cause adverse health effects
Published pricing lives on the brand's own site, and across the telehealth GLP-1 market monthly totals as of April 2026 fall roughly between $200 and $700+, with wide variance
But heres what we know from recent research: A 2025 study presented at ENDO showed that postmenopausal women using tirzepatide plus hormone replacement therapy (HRT) lost significantly more weight (17% total body weight) compared to women using tirzepatide alone (14%)
Researchers believe that hair loss during GLP-1 treatment is more related to underlying conditions than the drug itself
Regulatory context every buyer needs in June 2026: On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing bulks list - the pathway that enabled large-scale compounding
US$ 23.75
US$ 20.42
US$ 25.12
US$ 29.28
US$ 20.14
US$ 20.78
